WO2011017143A3 - Compositions et méthodes de préparation de lymphocytes t cytotoxiques alloréactifs - Google Patents

Compositions et méthodes de préparation de lymphocytes t cytotoxiques alloréactifs Download PDF

Info

Publication number
WO2011017143A3
WO2011017143A3 PCT/US2010/043470 US2010043470W WO2011017143A3 WO 2011017143 A3 WO2011017143 A3 WO 2011017143A3 US 2010043470 W US2010043470 W US 2010043470W WO 2011017143 A3 WO2011017143 A3 WO 2011017143A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
compositions
methods
alloreactive cytotoxic
preparing
Prior art date
Application number
PCT/US2010/043470
Other languages
English (en)
Other versions
WO2011017143A2 (fr
Inventor
Carol A. Kruse
Original Assignee
Promising Future, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Promising Future, Llc filed Critical Promising Future, Llc
Priority to AU2010281369A priority Critical patent/AU2010281369B2/en
Priority to EP10806916.2A priority patent/EP2459707B1/fr
Priority to CA2772280A priority patent/CA2772280C/fr
Publication of WO2011017143A2 publication Critical patent/WO2011017143A2/fr
Publication of WO2011017143A3 publication Critical patent/WO2011017143A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2301—Interleukin-1 (IL-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention a pour objet des compositions et des méthodes de préparation de lymphocytes T cytotoxiques thérapeutiques. Dans certains modes de réalisation, de tels lymphocytes T sont produits par l'activation des cellules donatrices par les cellules stimulatrices du patient.
PCT/US2010/043470 2009-07-28 2010-07-28 Compositions et méthodes de préparation de lymphocytes t cytotoxiques alloréactifs WO2011017143A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2010281369A AU2010281369B2 (en) 2009-07-28 2010-07-28 Compositions and methods of preparing alloreactive cytotoxic T cells
EP10806916.2A EP2459707B1 (fr) 2009-07-28 2010-07-28 Compositions et méthodes de préparation de lymphocytes t cytotoxiques alloréactifs
CA2772280A CA2772280C (fr) 2009-07-28 2010-07-28 Compositions et methodes de preparation de lymphocytes t cytotoxiques alloreactifs

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US22922909P 2009-07-28 2009-07-28
US22923309P 2009-07-28 2009-07-28
US61/229,229 2009-07-28
US61/229,233 2009-07-28
US12/844,516 2010-07-27
US12/844,516 US8586359B2 (en) 2009-07-28 2010-07-27 Compositions and methods of preparing alloreactive cytotoxic T cells

Publications (2)

Publication Number Publication Date
WO2011017143A2 WO2011017143A2 (fr) 2011-02-10
WO2011017143A3 true WO2011017143A3 (fr) 2011-06-16

Family

ID=43527243

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2010/043470 WO2011017143A2 (fr) 2009-07-28 2010-07-28 Compositions et méthodes de préparation de lymphocytes t cytotoxiques alloréactifs
PCT/US2010/043502 WO2011017151A2 (fr) 2009-07-28 2010-07-28 Méthodes d’appariement pour la préparation de lymphocytes t cytotoxiques alloréactifs

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2010/043502 WO2011017151A2 (fr) 2009-07-28 2010-07-28 Méthodes d’appariement pour la préparation de lymphocytes t cytotoxiques alloréactifs

Country Status (5)

Country Link
US (2) US8467973B2 (fr)
EP (2) EP2459707B1 (fr)
AU (2) AU2010281377B2 (fr)
CA (2) CA2772280C (fr)
WO (2) WO2011017143A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE029424T2 (en) 2009-01-15 2017-02-28 Adaptive Biotechnologies Corp Adaptive immunity profiling and a method for producing monoclonal antibodies
US8666674B2 (en) * 2009-07-28 2014-03-04 Promising Future, Llc Pairing processes for preparing reactive cytotoxic T cells
DK2831276T3 (da) 2012-05-08 2016-08-01 Adaptive Biotechnologies Corp Sammensætninger og fremgangsmåde til at måle og kalibrere amplifikations-bias i multipleks-PCR-reaktioner
US9708657B2 (en) 2013-07-01 2017-07-18 Adaptive Biotechnologies Corp. Method for generating clonotype profiles using sequence tags
US11390921B2 (en) 2014-04-01 2022-07-19 Adaptive Biotechnologies Corporation Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
CA2966201A1 (fr) 2014-10-29 2016-05-06 Adaptive Biotechnologies Corp. Detection simultanee hautement multiplexee d'acides nucleiques codant pour des heterodimeres de recepteurs de l'immunite adaptative apparies a partir de nombreux echantillons
BR112017009475B1 (pt) * 2014-11-05 2021-10-05 Memorial Sloan Kettering Cancer Center Métodos de seleção de uma linhagem de células t e de um doador das mesmas, sistema de computador para selecionar uma linhagem de células t, meio legível por computador, uso de uma população de células t e método para a obtenção de uma linhagem de células t
AU2016222788B2 (en) * 2015-02-24 2022-03-31 Adaptive Biotechnologies Corp. Methods for diagnosing infectious disease and determining HLA status using immune repertoire sequencing
AU2016242967B2 (en) 2015-04-01 2021-07-01 Adaptive Biotechnologies Corp. Method of identifying human compatible T cell receptors specific for an antigenic target
CA3029813A1 (fr) 2016-06-13 2017-12-21 Torque Therapeutics, Inc. Methodes et procedes pour favoriser la fonction des cellules immunitaires
US10428325B1 (en) 2016-09-21 2019-10-01 Adaptive Biotechnologies Corporation Identification of antigen-specific B cell receptors
EP3678701A4 (fr) 2017-09-05 2021-12-01 Torque Therapeutics, Inc. Compositions protéiques thérapeutiques et procédés de préparation et d'utilisation de celles-ci
US11254980B1 (en) 2017-11-29 2022-02-22 Adaptive Biotechnologies Corporation Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements
EP3737394A4 (fr) * 2018-01-08 2021-11-10 Atara Biotherapeutics, Inc. Systèmes et procédés de distribution de thérapies cellulaires

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US5314813A (en) * 1992-02-19 1994-05-24 Scripps Research Institute Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines
WO1994002156A1 (fr) * 1992-07-16 1994-02-03 The Board Of Trustees Of Leland Stanford Junior University Procedes d'utilisation de cellules dendritiques pour activer des lymphocytes t
US6821778B1 (en) * 1993-12-01 2004-11-23 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cells
WO1997022349A1 (fr) * 1995-12-20 1997-06-26 The Board Of Trustees Of The Leland Stanford Junior University Procedes relatifs a l'activation de lymphocytes t in vivo par des cellules dendritiques a impulsion d'antigene
PT879282E (pt) * 1996-01-17 2003-11-28 Imp College Innovations Ltd Imunoterapia utilizando linfocitos t citotoxicos (ctl)
US6734014B1 (en) 1996-02-08 2004-05-11 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating T cells
JP2002516562A (ja) * 1996-03-04 2002-06-04 ターゲティッド ジェネティックス コーポレイション Ｔリンパ球のインビトロ増殖のための改変された迅速な拡大方法（「改変ｒｅｍ」）
AU2002361468A1 (en) * 2001-08-14 2003-03-18 The Government Of The United States Of America As Represented By The Secretary Of Health And Human S Method for rapid generation of mature dendritic cells
GB0700058D0 (en) * 2007-01-03 2007-02-07 Scancell Aps Anti-tumor vaccine based on normal cells
US8666674B2 (en) * 2009-07-28 2014-03-04 Promising Future, Llc Pairing processes for preparing reactive cytotoxic T cells

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
KRONIK, N. ET AL.: "Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics", CANCER IMMUNOL. IMMUNOTHER., vol. 57, no. 3, March 2008 (2008-03-01), pages 425 - 439, XP019586701 *
NISHIOKA, Y. ET AL.: "Differential effects of IL-12 on the generation of allo reactive CTL mediated by murine and human dendritic cells: a critical role for nitric oxide", J. LEUKOC. BIOL., vol. 73, no. 5, May 2003 (2003-05-01), pages 621 - 629, XP008151878 *
SPECHT J.M. ET AL.: "Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases.", J. EXP. MED., vol. 186, no. 8, 20 October 1997 (1997-10-20), pages 1213 - 1221, XP002148420 *
TAVAKOLI, S. ET AL.: "Phenotype and function of monocyte derived dendritic ce11s in chronic hepatitis B virus infection", GEN. VIROL., vol. 85, October 2004 (2004-10-01), pages 2829 - 2836, XP008151874 *
TOSCH, C. ET AL.: "Adenovirus-mediated gene transfer of pathogen-associated molecular patterns for cancer immunotherapy", CANCER GENE THER., vol. 16, no. 4, April 2009 (2009-04-01), pages 310 - 319, XP008151876 *

Also Published As

Publication number Publication date
US8586359B2 (en) 2013-11-19
US8467973B2 (en) 2013-06-18
EP2459731B1 (fr) 2018-06-20
US20110027245A1 (en) 2011-02-03
EP2459731A2 (fr) 2012-06-06
EP2459707A2 (fr) 2012-06-06
EP2459707B1 (fr) 2017-10-04
AU2010281377B2 (en) 2014-09-18
CA2772280C (fr) 2017-01-03
EP2459731A4 (fr) 2013-03-13
CA2772326C (fr) 2017-04-18
WO2011017151A3 (fr) 2011-06-23
EP2459707A4 (fr) 2013-08-14
CA2772326A1 (fr) 2011-02-10
CA2772280A1 (fr) 2011-02-10
US20110027244A1 (en) 2011-02-03
WO2011017151A2 (fr) 2011-02-10
AU2010281377A1 (en) 2012-03-15
AU2010281369B2 (en) 2015-07-09
WO2011017143A2 (fr) 2011-02-10
AU2010281369A1 (en) 2012-03-15

Similar Documents

Publication Publication Date Title
WO2011017143A3 (fr) Compositions et méthodes de préparation de lymphocytes t cytotoxiques alloréactifs
AU2018256579A1 (en) Methods for preparing a skin graft
EP4279513A3 (fr) Agent thérapeutique induisant la cytotoxicité
WO2013040078A3 (fr) Tissus artificiels pour des utilisations en recherche in vitro, puces de ces tissus et procédés de fabrication correspondants
MX2011007930A (es) Conjugados de insulina cristalina.
WO2014186469A3 (fr) Application à des humains de lymphocytes t comprenant un récepteur antigénique chimérique (car)
AU2015213336B2 (en) Novel conjugates of CC-1065 analogs and bifunctional linkers
WO2012048099A3 (fr) Cellules chargées de nanoparticules
MY158992A (en) Forms of rifaximin and uses thereof
JOP20110402B1 (ar) الأجسام المضادة ل cd38
WO2010105728A3 (fr) Implant rétinien actif
WO2010108126A3 (fr) Compositions de reprogrammation et procédés d'utilisation de celles-ci
MX347893B (es) Conjugados de farmaco y anticuerpo humano contra factor de tejido.
WO2012003377A3 (fr) Procédé de préparation de tissu chorial et produits dérivés dudit tissu
MX340953B (es) Anticuerpos anti receptor del factor de necrosis tumoral inducido por glucocorticoides.
WO2011082038A3 (fr) Compositions de reprogrammation améliorées
MY159971A (en) Multipotent/pluripotent cells and methods
WO2012006440A3 (fr) Production de cellules endothéliales par programmation
WO2009151907A3 (fr) Compositions et procédés permettant d'utiliser des cellules pour traiter le tissu cardiaque
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
WO2012031164A3 (fr) Administration de médicaments par réseaux de nanotubes de carbone
WO2009095261A3 (fr) Compositions vaccinales
WO2012048170A3 (fr) Animaux humanisés par ingénierie tissulaire et leurs utilisations
MX344303B (es) Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
WO2011100330A3 (fr) Compositions et procédés de prévention ou de traitement d'une infection par un parvovirus humain

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10806916

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010281369

Country of ref document: AU

REEP Request for entry into the european phase

Ref document number: 2010806916

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2772280

Country of ref document: CA

Ref document number: 2010806916

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2010281369

Country of ref document: AU

Date of ref document: 20100728

Kind code of ref document: A